Opsidio, founded in 2012 and headquartered in Bryn Mawr, Pennsylvania, is a pre-clinical stage biotechnology company focused on developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company's core mission is to break the cycle of chronic inflammation and provide remedies for millions affected by severe diseases such as organ fibrosis. Opsidio aims to control these diseases through innovative biotechnological solutions.
Notable affiliated individuals and investors include leading scientists and venture capitalists specializing in biotech innovations. Opsidio has achieved significant milestones, including the initiation of a Phase 2 study for moderate to severe chronic inflammation conditions. The company's impact lies in its potential to transform treatment paradigms for chronic inflammatory diseases, offering hope and improved quality of life for patients worldwide.
